Drug Trial Radar · NCT04845399
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Apr 16, 2021
Primary completion
Jun 26, 2021
Study completion Jun 26, 2021
Sponsor
- Lead sponsor
- Zhengzhou Gensciences IncIndustry
- Sponsor type
- Industry
- Collaborators
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.
- First posted
- Apr 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.
Conditions
- Hemophilia A
Interventions
Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug
Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rates (ABR).Time frame: For the duration of study participation, 6 months.
- Number of target joints.Time frame: For the duration of study participation, 6 months.
- Annualized Joint Bleeding Rate (AJBR)Time frame: For the duration of study participation, 6 months.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Capital Medical University affiliated Beijing Children's Hospital
Beijing, Beijing Municipality, China
Chongqing Three Gorges Central Hospital
Chongqing, Chongqing Municipality, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangzhou, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangzhou, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Henan provincial People's Hospital
Zhengzhou, He'nan, China
Henan Cancer Hospital
Zhengzhou, He'nan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Jinan central hospital
Ji'nan, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.